ace-011 has been researched along with Pulmonary-Arterial-Hypertension* in 10 studies
3 trial(s) available for ace-011 and Pulmonary-Arterial-Hypertension
Article | Year |
---|---|
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo. This report characterises the longer-term safety and efficacy of sotatercept in the PULSAR open-label extension. We report cumulative safety, and efficacy at months 18-24, for all participants treated with sotatercept.. PULSAR was a phase 2, randomised, double-blind, placebo-controlled study followed by an open-label extension, which evaluated sotatercept on top of background pulmonary arterial hypertension therapy in adults. Participants originally randomised to placebo were re-randomised 1:1 to sotatercept 0.3 or 0.7 mg·kg. Of 106 participants enrolled in the PULSAR study, 97 continued into the extension period. Serious treatment-emergent adverse events were reported in 32 (30.8%) participants; 10 (9.6%) reported treatment-emergent adverse events leading to study discontinuation. Three (2.9%) participants died, none considered related to study drug. The placebo-crossed group demonstrated significant improvement across primary and secondary endpoints and clinical efficacy was maintained in the continued-sotatercept group.. These results support the longer-term safety and durability of clinical benefit of sotatercept for pulmonary arterial hypertension. Topics: Adult; DEAE-Dextran; Double-Blind Method; Familial Primary Pulmonary Hypertension; Humans; Pulmonary Arterial Hypertension; Treatment Outcome | 2023 |
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Pulmonary arterial hypertension is a progressive disease involving proliferative remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated morbidity and mortality remain high. Sotatercept is a fusion protein that traps activins and growth differentiation factors involved in pulmonary arterial hypertension.. We conducted a multicenter, double-blind, phase 3 trial in which adults with pulmonary arterial hypertension (World Health Organization [WHO] functional class II or III) who were receiving stable background therapy were randomly assigned in a 1:1 ratio to receive subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; target dose, 0.7 mg per kilogram) or placebo every 3 weeks. The primary end point was the change from baseline at week 24 in the 6-minute walk distance. Nine secondary end points, tested hierarchically in the following order, were multicomponent improvement, change in pulmonary vascular resistance, change in N-terminal pro-B-type natriuretic peptide level, improvement in WHO functional class, time to death or clinical worsening, French risk score, and changes in the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Physical Impacts, Cardiopulmonary Symptoms, and Cognitive/Emotional Impacts domain scores; all were assessed at week 24 except time to death or clinical worsening, which was assessed when the last patient completed the week 24 visit.. A total of 163 patients were assigned to receive sotatercept and 160 to receive placebo. The median change from baseline at week 24 in the 6-minute walk distance was 34.4 m (95% confidence interval [CI], 33.0 to 35.5) in the sotatercept group and 1.0 m (95% CI, -0.3 to 3.5) in the placebo group. The Hodges-Lehmann estimate of the difference between the sotatercept and placebo groups in the change from baseline at week 24 in the 6-minute walk distance was 40.8 m (95% CI, 27.5 to 54.1; P<0.001). The first eight secondary end points were significantly improved with sotatercept as compared with placebo, whereas the PAH-SYMPACT Cognitive/Emotional Impacts domain score was not. Adverse events that occurred more frequently with sotatercept than with placebo included epistaxis, dizziness, telangiectasia, increased hemoglobin levels, thrombocytopenia, and increased blood pressure.. In patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo. (Funded by Acceleron Pharma, a subsidiary of MSD; STELLAR ClinicalTrials.gov number, NCT04576988.). Topics: Adult; Cardiovascular Agents; Double-Blind Method; Exercise Tolerance; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pulmonary Arterial Hypertension; Recombinant Fusion Proteins; Respiratory System Agents; Treatment Outcome; Vascular Resistance; Walk Test | 2023 |
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins and growth differentiation factors in the attempt to restore balance between growth-promoting and growth-inhibiting signaling pathways.. In this 24-week multicenter trial, we randomly assigned 106 adults who were receiving background therapy for pulmonary arterial hypertension to receive subcutaneous sotatercept at a dose of 0.3 mg per kilogram of body weight every 3 weeks or 0.7 mg per kilogram every 3 weeks or placebo. The primary end point was the change from baseline to week 24 in pulmonary vascular resistance.. Baseline characteristics were similar among the three groups. The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group in the change from baseline to week 24 in pulmonary vascular resistance was -145.8 dyn · sec · cm. Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension. (Funded by Acceleron Pharma; PULSAR ClinicalTrials.gov number, NCT03496207.). Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Tolerance; Female; Humans; Injections, Subcutaneous; Least-Squares Analysis; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pulmonary Arterial Hypertension; Recombinant Fusion Proteins; Thrombocytopenia; Transforming Growth Factor beta; Vascular Resistance; Walk Test | 2021 |
7 other study(ies) available for ace-011 and Pulmonary-Arterial-Hypertension
Article | Year |
---|---|
Merck bets on sotatercept in pulmonary arterial hypertension.
Topics: Humans; Pulmonary Arterial Hypertension; Recombinant Fusion Proteins | 2023 |
Sotatercept for pulmonary arterial hypertension: something old and something new.
Topics: DEAE-Dextran; Familial Primary Pulmonary Hypertension; Humans; Pulmonary Arterial Hypertension; Recombinant Fusion Proteins | 2023 |
Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension.
Topics: Familial Primary Pulmonary Hypertension; Gases; Humans; Lung; Pulmonary Arterial Hypertension; Recombinant Fusion Proteins | 2023 |
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle.
Topics: Familial Primary Pulmonary Hypertension; Heart; Heart Ventricles; Hemodynamics; Humans; Pulmonary Arterial Hypertension | 2023 |
Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein that improves cardiopulmonary function in patients with pulmonary arterial hypertension (PAH) by selectively trapping activins and growth differentiation factors. However, the cellular and molecular mechanisms of ActRIIA-Fc action are incompletely understood. Here, we determined through genome-wide expression profiling that inflammatory and immune responses are prominently upregulated in the lungs of a Sugen-hypoxia rat model of severe angio-obliterative PAH, concordant with profiles observed in PAH patients. Therapeutic treatment with ActRIIA-Fc-but not with a vasodilator-strikingly reversed proinflammatory and proliferative gene expression profiles and normalized macrophage infiltration in diseased rodent lungs. Furthermore, ActRIIA-Fc normalized pulmonary macrophage infiltration and corrected cardiopulmonary structure and function in Bmpr2 haploinsufficient mice subjected to hypoxia, a model of heritable PAH. Three high-affinity ligands of ActRIIA-Fc each induced macrophage activation in vitro, and their combined immunoneutralization in PAH rats produced cardiopulmonary benefits comparable to those elicited by ActRIIA-Fc. Our results in complementary experimental and genetic models of PAH reveal therapeutic anti-inflammatory activities of ActRIIA-Fc that, together with its known anti-proliferative effects on vascular cell types, could underlie clinical activity of sotatercept as either monotherapy or add-on to current PAH therapies. Topics: Animals; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Hypoxia; Inflammation; Mice; Pulmonary Arterial Hypertension; Rats; Recombinant Fusion Proteins | 2022 |
Molecular Rescue in Pulmonary Arterial Hypertension.
Topics: Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Recombinant Fusion Proteins | 2021 |
Sotatercept for Pulmonary Arterial Hypertension.
Topics: Humans; Pulmonary Arterial Hypertension; Recombinant Fusion Proteins | 2021 |